India CFO Summit :Watch India's top CFOs reveal how to mitigate financial risks and maintain business continuity on November 24, 2020 at 12pm. Register now!
you are here: HomeNewsWorld
Last Updated : Apr 22, 2020 07:29 PM IST | Source: Reuters

Germany approves first trial of COVID-19 vaccine candidate

The trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people aged between 18 and 55 in the first stage, and on further people, including those at higher risk from the disease, in a second stage.

Reuters

Germany's vaccines regulator approved live human testing of a potential vaccine against the Covid-19 virus developed by German biotech company BioNTech, the regulator said in a statement on Wednesday.

The trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people aged between 18 and 55 in the first stage, and on further people, including those at higher risk from the disease, in a second stage.

BioNTech said it was developing the vaccine candidate, named BNT162, together with its partner, pharma giant Pfizer. Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there.
First Published on Apr 22, 2020 03:40 pm
Sections